The massive influx of new capital coming into the private credit market through life insurers and business development companies (BDCs) could lead to an erosion of quality and returns, Adams ...

Most biopharma and life sciences hedge funds finally posted strong results in July. Even so, many remain deep in the red for the year thanks in part to the Trump administration’s opposition to ...

Despite more allocators depending on active management to generate returns amid volatility, the numbers continue to show that ...

The Pennsylvania Municipal Retirement System is getting into private markets for the first time in its history.After ...

Greenlight Capital turned much more bearish in the second quarter.The hedge fund headed by David Einhorn had already been lukewarm about equities for some time, anticipating a recession. As of the ...

Currently serving as Managing Director for the Middle East and Africa at MFS Investment Management, Tohmé brings extensive ...

Venture capital activity in the biopharma and life sciences industries has significantly declined from last year’s near-record pace. This is especially apparent among hedge fund firms with ...

Greenlight Capital has shed all of this year’s gains after suffering another large monthly loss.The long-short hedge fund headed by David Einhorn dropped 4.1 percent in July and is now down 0.1 ...

When Scott Bok left his home in Grand Rapids, Michigan, to attend the University of Pennsylvania in 1977, he had no plans for ...

For more than 55 years, Institutional Investor has delivered the news and analysis that investment professionals need to succeed and stay relevant. Our coverage of the global asset management ...

The firm that real estate investor and philanthropist Sam Zell founded to manage his wealth, Equity Group Investments, is ...